In summary, we have identified and characterized G1T38 as a novel, potent, selective and orally bioavailable small molecule inhibitor of CDK4/6 that shows significant efficacy in CDK4/6 dependent tumors by effectively inhibiting tumor growth without causing severe neutropenia. The gene discussed is CDK4; the disease is neutropenia.